PerkinElmer, Inc. Announces New Innovations to Strengthen Drug Discovery Product Portfolio

ST. LOUIS--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today announced the release of eight new AlphaLISA™ immunoassay kits in conjunction with the Society for Biomolecular Sciences’ (SBS) 14th Annual Conference and Exhibition. These latest innovations include research reagents and assays for investigating HIV, cancer, central nervous system disorders, cardiovascular disorders, and diabetes(a).